PT  - JOURNAL ARTICLE
AU  - Terrance D. Barrett
AU  - James K. Hennan
AU  - Rory M. Marks
AU  - Benedict R. Lucchesi
TI  - C-Reactive-Protein-Associated Increase in Myocardial Infarct Size After Ischemia/Reperfusion
AID  - 10.1124/jpet.102.040600
DP  - 2002 Dec 01
TA  - Journal of Pharmacology and Experimental Therapeutics
PG  - 1007--1013
VI  - 303
IP  - 3
4099  - http://jpet.aspetjournals.org/content/303/3/1007.short
4100  - http://jpet.aspetjournals.org/content/303/3/1007.full
SO  - J Pharmacol Exp Ther2002 Dec 01; 303
AB  - C-Reactive protein (CRP), a marker for acute inflammation, is associated with increased risk of cardiovascular events. The mechanism underlying this association is uncertain. An acute inflammatory response was induced in rabbits by subcutaneous injection of croton oil (CO) 1 to 3 days before 30 min of regional myocardial ischemia/180 min of reperfusion. CO treatment increased plasma CRP from below the limit of detection to 2.5 ± 0.5 mg/dl and was associated with an increase in infarct size expressed as percentage of risk region [32 ± 6% vehicle controls (n = 7) to 47 ± 9% CO-treated rabbits (n = 7;P < 0.05]. After 10 min of ischemia and 180 min reperfusion, no infarct was found in controls; however, an infarct of 7 ± 1% was found in CO-treated rabbits (P < 0.05; CRP, 2.3 ± 0.4 mg/dl). The CRP-related increase in infarct size was not observed in croton oil-treated, C6-deficient rabbits (n = 5/group), indicating the involvement of complement. In these rabbits, infarct size was 22 ± 2% (P < 0.05) despite having plasma CRP of 4.3 ± 0.4 mg/dl. The CRP-associated increase in infarct size was ameliorated by pretreatment with heparin (n = 7; infarct size 33 ± 3%; CRP, 2.3 ± 0.3 mg/dl;P < 0.05) or N-acetylheparin (n = 7; infarct size 23 ± 4%; CRP, 3.1 ± 0.5 mg/dl; P < 0.05). These observations may explain why increased serum CRP is associated with an augmented risk for cardiovascular events.